VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) --

WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that

in collaboration with CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS"), a biopharmaceutical company,

it has identified several leading medical institutions in Poland to conduct its Berubicin Phase 2 clinical trial in adults with glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.